Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non‐Small‐Cell Lung Cancer

BioMed Research International - Tập 2011 Số 1 - 2011
Takayuki Kosaka1, Ei Yamaki1, Akira Mogi1, Hiroyuki Kuwano1
1Department of General Surgical Science, Graduate School of Medicine, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511

Tóm tắt

Gefitinib and erlotinib, which are epidermal growth factor receptor‐ (EGFR‐) specific tyrosine kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell lung cancer (NSCLC). Currently, the search for EGFR gene mutations is becoming essential for the treatment of NSCLC since these have been identified as predictive factors for drug sensitivity. On the other hand, in almost all patients responsive to EGFR‐TKIs, acquired resistance is a major clinical problem. Mechanisms of acquired resistance reported in the past few years include secondary mutation of the EGFR gene, amplification of the MET gene, and overexpression of HGF; novel pharmaceutical agents are currently being developed to overcome resistance. This review focuses on these mechanisms of acquired resistance to EGFR‐TKIs and discusses how they can be overcome.

Từ khóa


Tài liệu tham khảo

10.1001/jama.290.16.2149

10.1200/JCO.2003.10.038

10.1126/science.1099314

10.1056/NEJMoa040938

10.1073/pnas.0405220101

10.1111/j.1349-7006.2007.00607.x

10.1056/NEJMoa0810699

10.1016/S1470-2045(09)70364-X

10.1056/NEJMoa0909530

10.1371/journal.pmed.0020313

10.1158/1078-0432.CCR-07-5123

Pao W., 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Medicine, 2

Yano S., 2010, Studies for mechanism of drug resistance to EGFR-TKI, Gan To Kagaku Ryoho, 37, 1463

10.1056/NEJMoa044238

Pao W., 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Medicine, 2

10.1073/pnas.0502860102

10.1073/pnas.0709662105

10.1182/blood-2004-08-3097

10.1158/1078-0432.CCR-04-2245

10.1074/jbc.M211158200

10.1038/nsmb.1486

10.1158/1078-0432.CCR-06-1570

10.1158/1078-0432.CCR-06-0714

10.1126/science.1141478

10.1158/0008-5472.CAN-06-1951

10.1056/NEJMoa0800668

10.1182/blood.V100.3.1014

10.1182/blood-2002-06-1756

Toyooka S., 2005, EGFR mutation and response of lung cancer to gefitinib, New England Journal of Medicine, 352

10.1056/NEJM200507143530217

10.1038/ng1671

10.1158/0008-5472.CAN-07-0217

10.1158/0008-5472.CAN-06-4293

10.1158/0008-5472.CAN-06-4625

10.1073/pnas.0710370104

10.1111/j.1349-7006.2008.00916.x

10.1097/JTO.0b013e3181913e0e

10.1002/ijc.24150

10.1097/JTO.0b013e318168d9d4

10.1016/j.ccr.2009.11.022

10.1158/0008-5472.CAN-08-1643

10.1016/j.lungcan.2009.05.022

10.1371/journal.pmed.0040315

10.1158/1078-0432.CCR-08-0151

Guix M., 2008, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins, Journal of Clinical Investigation, 118, 2609

10.1200/JCO.2009.27.9414

10.1158/1078-0432.CCR-08-1978

10.1038/sj.bjc.6604108

10.1200/JCO.2009.26.7278

10.1158/0008-5472.CAN-07-1885

10.1038/nature08622

10.1038/onc.2009.526

10.1158/1078-0432.CCR-09-1204

10.1158/1078-0432.CCR-09-1001

10.1158/0008-5472.CAN-09-3620

Thông tin
Thông tin xuất bản

BioMed Research International

Tập 2011 Số 1

Thông tin tác giả